In an effort to get drug regulators in the various EU member states on the same page, the EMA issued a Sept. 19 statement confirming that all biosimilars approved in the EU are interchangeable with other approved biosimilars referencing the same biologic, as well as the reference biologic itself.

Despite wide availability and coverage for colonoscopy, many patients diagnosed with colorectal cancer (CRC) have never undergone the recommended screening procedure for the malignancy and its precursors. As a result, the cancer has already spread in the majority of cases at the time of diagnosis. CRC remains the third most common cancer diagnosed in the U.S. and the second leading cause of cancer death for both men and women.

The association of health care professionals in Normandy (APRIC) and the regional support group for the development of e-health in Normandy released new data on the importance of home telemonitoring in heart failure. Patients participating in the Suivi Clinique à Domicile (SCAD) heart failure home telemonitoring program experience less re-hospitalizations and lower death rates than patients with the same pathology but not on the program.

Angioplasty and stenting have combined to become the standard of care for patients with myocardia that sustained damage due to an infarct, but a new study suggests that some of these patients are no worse off with medical management compared to a trip to the cath lab. 

Researchers from ESPCI Paris (Paris University for Industrial Physics and Chemistry), are working on a novel functional neuroimaging technique for measuring whole-brain activity dynamically at the microscopic level.

Thirteen months after Illumina Inc. and Grail Inc. merged, prior to regulatory approval, the deal has taken a turn for the worse. The prognosis looked better following an administrative law judge’s ruling Sept. 1 against the U.S. Federal Trade Commission’s lawsuit seeking to block the transaction, but the European Commission (EC) issued a decision Sept. 6 prohibiting the deal based on the likelihood that a merger would stifle innovation and limit choices in the early cancer detection liquid biopsy market.

Collagen is the most abundant protein in the human body, which would seem to make it an unlikely source for an immunotherapy target. But it is where researchers from Immatics Biotechnologies GmbH and the University of Pennsylvania have found a target that was expressed on stromal cells in a number of different solid tumors, but very rare in normal tissues.

International research project Multicentre Epilepsy Lesion Detection (MELD), led by University College London, has developed artificial intelligence software that can identify minute brain anomalies that lead to epilepsy seizures. These anomalies, known as focal cortical dysplasia, can often be treated with surgery but are difficult to visualize on an MRI.